---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-040590"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T21:46:11.677234+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Assembly Bio Q2 net loss $16.9M ($0.32/sh); cash $59.8M; ABI-5366 on track for H1 2024 clinic

## Summary
- Net loss $16.9M ($0.32 per share) vs $24.5M ($0.51) in Q2 2022; R&D expense down to $12.5M from $17.8M.
- Cash, cash equivalents and marketable securities $59.8M as of June 30, 2023; projected to fund ops through Q3 2024.
- Herpesvirus candidate ABI-5366 entered GLP toxicology; IND/CTA submission planned for H1 2024.
- Second development candidate nomination expected in 2023; additional candidate to enter clinic by year-end 2024.
- Three abstracts accepted for 2023 International HBV Meeting in Kobe, Japan (Sept 19-23).

## SEC filing metadata
- accession: 0000950170-23-040590
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000095017023040590/0000950170-23-040590-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000095017023040590/asmb-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-040590
- JSON: https://secwatch.observer/filing/0000950170-23-040590.json
- Plain text: https://secwatch.observer/filing/0000950170-23-040590.txt

## Key facts
- Earnings Releases
  ASSEMBLY BIOSCIENCES, INC. reported the quarter ended June 30, 2023 results: net income $16.9 million, or $0.32 per basic and diluted share, EPS $0.32 per basic and diluted share.
  - Period: the quarter ended June 30, 2023
  - Net income: $16.9 million, or $0.32 per basic and diluted share
  - EPS: $0.32 per basic and diluted share
  - Result: reported results
  source text: Net loss attributable to common stockholders was $16.9 million, or $0.32 per basic and diluted share, for the three months ended June 30, 2023, compared to $24.5 million, or $0.51 per basic and diluted share, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1426800/000095017023040590/0000950170-23-040590-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.